Chemo Fog pp 70-76 | Cite as

Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment

  • Robert B. Raffa
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 678)


The chemotherapy-related cognitive impairment (chemo fog/chemo brain) that is reported by many cancer patients is supported to varying degrees primarily by evidence from prospective and retrospective clinical studies. However, the inherent difficulty in conducting such trials (including ethical issues of placebo-controlled designs), the fact that the cognitive impairment is characteristically subtle and that the patients might be able to compensate for their deficits during testing, gives rise to questions about the degree and the extent of the problem—and indeed even if there is a problem. Neuroimaging techniques might offer additional insight. This chapter is a succinct summary of a more expanded review of the relatively few such studies.1


Breast Cancer Adjuvant Chemotherapy Clin Oncol Breast Cancer Survivor Standardize Neuropsychological Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Raffa RB. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in ‘chemo-fog’/‘chemo-brain’. J Clin Pharm Ther, in press..Google Scholar
  2. 2.
    Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 2002; 3(suppl 3):S84–S90.PubMedCrossRefGoogle Scholar
  3. 3.
    Tannock IF, Ahles TA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233–2239.PubMedCrossRefGoogle Scholar
  4. 4.
    Castellon SA, Silverman DHS, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 2005; 92:199–206.PubMedCrossRefGoogle Scholar
  5. 5.
    Falleti MG, Sanfilippo A, Maruff P et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cognitn 2005; 59:60–70.CrossRefGoogle Scholar
  6. 6.
    Welzel G, Steinworth S, Wenz F. Cognitive effects of chemotherapy and/or cranial irradiatipon in adults. Strahlentherapie und Onkologie 2005; 181:141–156.PubMedCrossRefGoogle Scholar
  7. 7.
    Correa DD, Ahles TA. Cognitive adverse effects of chemotherapy in breast cancer patients. Curr Opin Supportive Palliative Care 2007; 1:57–62.CrossRefGoogle Scholar
  8. 8.
    Raffa RB, Duong PV, Finney J et al. Is ‘chemo-fog’/‘chemo-brain’ caused by cancer chemotherapy? J Clin Pharm Thera 2006; 31:129–138.CrossRefGoogle Scholar
  9. 9.
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4:61–66.CrossRefGoogle Scholar
  10. 10.
    van Dam FSAM, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Instit 1998; 90:210–218.CrossRefGoogle Scholar
  11. 11.
    Schagen SB, van Dam FSAM, Muller MJ et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640–650.PubMedCrossRefGoogle Scholar
  12. 12.
    Brezden CB, Phillips K-A, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:2695–2701.PubMedGoogle Scholar
  13. 13.
    Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485–493.PubMedCrossRefGoogle Scholar
  14. 14.
    O’Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3(suppl 3):S116–S120.PubMedCrossRefGoogle Scholar
  15. 15.
    Schagen SB, Muller MJ, Boogerd W et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Annal Oncol 2002; 13:1387–1397.CrossRefGoogle Scholar
  16. 16.
    Tchen N, Juffs HG, Downie FP et al. Cognitive changes, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer: a prospective matched cohort study. J Clin Oncol 2003; 21:4175–4183.PubMedCrossRefGoogle Scholar
  17. 17.
    Ganz PA, Desmond KA, Leedham B et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002; 94:39–49.PubMedCrossRefGoogle Scholar
  18. 18.
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA (a Cancer Journal for Clinicians) 2006; 56:106–130.CrossRefGoogle Scholar
  19. 19.
    Donovan KA, Small BJ, Andrykowski MA et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005; 104:2499–2507.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Matsuda T, Takayama T, Tashiro M et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients—evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005; 12:279–287.PubMedCrossRefGoogle Scholar
  21. 21.
    Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Brit J Cancer 2006; 94:828–834.PubMedCrossRefGoogle Scholar
  22. 22.
    Kreukels BP, Schagen SB, Ridderinkhof KR et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 2005; 7:67–78.CrossRefGoogle Scholar
  23. 23.
    Kreukels BPC, Schagen SB, Ridderinkhof KR et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2006; 94:53–61.CrossRefGoogle Scholar
  24. 24.
    Sternberg S. The discovery of processing stages: extension of Donders’ method. Acta Psychologica 1969; 30:276–315.CrossRefGoogle Scholar
  25. 25.
    Sanders AF. Towards a model of stress and human performance. Acta Psychologica 1983; 53:61–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Sanders AF. Issues and trends in the debate on discrete vs. continuous processing of information. Acta Psychologica 1990; 74:123–167.CrossRefGoogle Scholar
  27. 27.
    Stemmer SM, Stears JC, Burton BS et al. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Amer J Neuroradiol 1994; 15:1267–1273.Google Scholar
  28. 28.
    Brown MS, Simon JH, Stemmer SM et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Amer J Neuroradiol 1995; 16:2013–2020.Google Scholar
  29. 29.
    Brown MS, Stemmer SM, Simon JH et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Amer J Neuroradiol 1998; 19:217–221.Google Scholar
  30. 30.
    Yoshikawa E, Matsuoka Y, Inagaki M et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 2005; 92:81–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Inagaki M, Yoshikawa E, Matsuoka Y et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007; 109:146–156.PubMedCrossRefGoogle Scholar
  32. 32.
    Ferguson Ferguson RJ, McDonald BC, Saykin AJ et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007; 25:3866–3870.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Silverman DHS, Dy CJ, Castellon SA et al. Altered frontocortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103:303–311.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Robert B. Raffa
    • 1
  1. 1.Department of Pharmaceutical SciencesTemple University School of PharmacyPhiladelphiaUSA

Personalised recommendations